Knockdown

Knockdown describes the experimental reduction of gene expression in cells or organisms without permanently altering the genome, typically achieved using RNA interference technologies such as siRNA, shRNA, or antisense oligonucleotides. Unlike gene knockout, which completely removes gene function, knockdown produces partial, controlled suppression allowing functional analysis while preserving cellular viability.

In pharmaceutical and biological research, knockdown studies enable identification of gene function, validation of drug targets, and investigation of disease mechanisms. Researchers assess how reduced expression affects cellular behaviour, signalling pathways, or disease phenotypes. Knockdown models support screening for therapeutic targets by demonstrating whether lowering a protein's activity produces beneficial effects. In drug discovery, knockdown experiments often precede chemical inhibition studies, confirming biological relevance before investing in compound development. Technical considerations include delivery efficiency, off-target effects, stability of suppression, and reproducibility. Advances in RNA delivery systems continue improving knockdown reliability. Knockdown technology remains a cornerstone of functional genomics, bridging molecular biology with translational medicine through controlled, reversible gene suppression.